<p><span class="legendSpanClass"><span class="xn-location">NEWARK, Del.</span>, June 6, 2025 /PRNewswire/ --</span></p>  <p><b><span id="spanHghlt8e28"><span class="xn-location">China's</span> influential innovative drug asset cooperation platform</span></b></p>  <p>BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration between <span class="xn-location">China's</span> biopharma sector and global markets, facilitating partnerships, therapeutic asset licensing, and investment networking.</p>  <p>The 5th annual BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors dominated the audience, with 61.66% holding C-suite, BD, or investment roles. The event facilitated 7,275 meeting requests. Confirmed deals across oncology, rare diseases, and next-gen modalities. MNCs including Merck &amp; Co., Pfizer and Bayer emerged as top targets, with key accounts receiving over 50 meeting requests each.</p>  <p><b>Key Insights from BIOS Discussions</b></p>  <p>Dr. <span class="xn-person">Yi Zhu</span>, Founder and CSO of Biokin Pharma, framed <span class="xn-location">China</span> as a &quot;translational research powerhouse&quot; uniquely positioned to de-risk high-impact modalities. &quot;Our cost-efficient clinical execution enables rapid validation of novel ADCs and gene-editing platforms,&quot; he noted, citing Biokin's Phase II PD-1xLAG-3 bispecific antibody as evidence of <span class="xn-location">China's</span> ability to advance complex biologics. His call for investors to prioritize high-risk, high-reward assets resonated across sessions, particularly as Chinese startups now contribute 38% of global ADC patents.</p>  <p><span class="xn-person">John Zhu</span>, CEO of DualityBio, challenged conventional innovation metrics during a standing-room-only session. &quot;True differentiation isn't about target novelty but biomarker-driven clinical value,&quot; he asserted, showcasing DualityBio's tumor-activated ADC linker technology. His critique of &quot;therapeutic crowding&quot; aligned with investor interest in <span class="xn-location">China's</span> precision medicine pipelines, particularly in NSCLC and triple-negative breast cancer.</p>  <p>Dr. Zhang Lianshan, EVP of Hengrui Pharma, grounded discussions in localization imperatives. &quot;Globalization starts with domestic validation,&quot; he emphasized, detailing Hengrui's strategy to leverage <span class="xn-location">China's</span> 140 million cancer patient registry for accelerated oncology trials. His case study on a Claudin 18.2-targeted therapy?봭ow in global Phase III?봦ighlighted <span class="xn-location">China's</span> evolving role from fast follower to protocol co-designer.</p>  <p><span class="xn-person">Jacky Jiang</span>, BD Head at CSPC Pharma, outlined a pragmatic blueprint for strategic asset curation. &quot;Align R&amp;D with unmet needs, technical strengths, and M&amp;A agility,&quot; he advised, referencing CSPC's recent acquisition of a CRISPR-Cas12Max delivery platform. His prediction that non-viral gene therapies will dominate rare disease investments by 2026 drew vigorous investor follow-ups.</p>  <p><b>40 companies gave roadshows and brought abundant assets</b></p>  <p>The BIOSeedin 2025 roadshow spotlighted <span class="xn-location">China's</span> accelerating leadership in next-generation therapies, with 40% of showcased assets featuring breakthrough modalities like Phase II PD-1xLAG-3 bispecifics for NSCLC, preclinical Claudin 18.2xCD3 T-cell engagers, and tumor microenvironment-activated ADC linkers?봳echnologies where Chinese firms now hold 32% of global patents. Rare disease innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic/CNS advances featured dual <span>GLP-1</span>/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer's mAbs. With 50% of programs in Phase I/II (including 10 breakthrough-designated assets) and two Phase III candidates nearing 2026 NDAs?봞 bispecific NSCLC antibody leveraging <span class="xn-location">China's</span> genomic databases and a non-opioid TRPV1-ATP analgesic?봳he portfolio underscores <span class="xn-location">China's</span> evolution from fast follower to global innovator, combining cost-efficient development with patient-centric therapeutic engineering.</p>  <p>Building on this year's success, BIOSeedin 2026 will expand its global footprint with dedicated tracks for European and North American attendees.</p>  <p>As Dr. <span class="xn-person">Zhu Yi</span> concluded, &quot;<span class="xn-location">China's</span> biotech sector is not just catching up?봧t's redefining innovation. We invite global partners to join this journey, where collaboration transcends borders and accelerates patient-centric breakthroughs.&quot;</p>  <p>Join us next year to explore investment opportunities, forge transformative partnerships, and shape the future of biopharma innovation.</p>  <p><a href="http://www.bioseedin.com/" target="_blank" rel="nofollow" style="color: #0000FF">www.bioseedin.com</a><br /><a href="mailto:service@bioseedin.com" target="_blank" rel="nofollow" style="color: #0000FF">service@bioseedin.com</a></p>